Merck Acquires Modifi Biosciences to Bolster Cancer Drug Pipeline

68

Merck, a leading pharmaceutical company, has announced the acquisition of Modifi Biosciences for up to $1.3 billion. This strategic move aims to bolster Merck’s oncology portfolio and address the potential decline in revenue from its blockbuster cancer immunotherapy, Keytruda, as patent expiration looms.

Modifi Biosciences, a pre-clinical stage biotech company, is developing a novel class of cancer therapies known as KL-50. These therapies are designed to selectively target and kill cancer cells by modifying their DNA. The acquisition of Modifi grants Merck access to this promising pipeline, which holds significant potential for the treatment of difficult-to-treat cancers, including glioblastomas.

Merck has been actively seeking out innovative therapies to replenish its pipeline and maintain its leadership position in the oncology market. The company’s $5.5 billion deal with Daiichi Sankyo last year to collaborate on antibody-drug conjugates further demonstrates its commitment to expanding its oncology offerings.

The acquisition of Modifi Biosciences is another step in Merck’s strategy to develop cutting-edge therapies that address unmet medical needs. By investing in promising early-stage companies, Merck aims to drive innovation and deliver transformative treatments to patients with cancer.